Review Article

Role of Posttranslational Modifications of Proteins in Cardiovascular Disease

Yong-Ping Liu, Tie-Ning Zhang, Ri Wen, Chun-Feng Liu, and Ni Yang

Department of Pediatrics, PICU, Shengjing Hospital of China Medical University, Shenyang, China

Correspondence should be addressed to Chun-Feng Liu; zhliu258@hotmail.com and Ni Yang; yangni616@hotmail.com

Received 22 March 2022; Accepted 23 June 2022; Published 9 July 2022

Academic Editor: Reiko Matsui

Copyright © 2022 Yong-Ping Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cardiovascular disease (CVD) has become a leading cause of mortality and morbidity globally, making it an urgent concern. Although some studies have been performed on CVD, its molecular mechanism remains largely unknown for all types of CVD. However, recent in vivo and in vitro studies have successfully identified the important roles of posttranslational modifications (PTMs) in various diseases, including CVD. Protein modification, also known as PTMs, refers to the chemical modification of specific amino acid residues after protein biosynthesis, which is a key process that can influence the activity or expression level of proteins. Studies on PTMs have contributed directly to improving the therapeutic strategies for CVD. In this review, we examined recent progress on PTMs and highlighted their importance in both physiological and pathological conditions of the cardiovascular system. Overall, the findings of this review contribute to the understanding of PTMs and their potential roles in the treatment of CVD.

1. Introduction

Cardiovascular disease (CVD) is a common disease caused by multiple factors and is the disease with the highest mortality and morbidity in the world, and its incidence is still on the rise globally [1]. For example, between 2010 and 2020, deaths from CVD have increased by 12.5% accounting for 31% of all deaths worldwide [2, 3]. Owing to the increasing incidence of CVD, CVD-related deaths are expected to exceed 23.6 million globally by 2030 [4]. More than 95% of CVD-related deaths can be attributed to the following causes: hypertensive heart disease, stroke, ischemic heart disease (IHD), cardiomyopathy, atrial fibrillation (AF), and rheumatic heart disease (RHD) [5]. The high mortality and morbidity rates of CVD are serious threats to human health and affect the quality of life, necessitating research attention. Currently available treatment approaches have not been effective in treating CVD; moreover, the molecular mechanisms of CVD have not been fully elucidated. However, it is believed that posttranslational modifications (PTMs) of various proteins play important roles in the development of CVD.

Protein modification, also known as PTMs, refers to the chemical modification of specific amino acid residues after protein biosynthesis [6], which is an important biochemical process that occurs at the protein level [7]. PTMs mainly include acetylation, phosphorylation, succinylation, glutathionylation, and SUMOylation. It is estimated that approximately two-thirds of proteins in the body undergo PTMs. Notably, PTMs involves almost all aspects of cell biology by regulating signaling pathways to maintain cell homeostasis. Previous studies have confirmed that PTMs are considered to be a biological mechanism that regulates the function of proteome, affecting protein stability, activity, subcellular localization of proteins, and proteins’ interactions [8]. Additionally, PTMs can regulate the catalysis and related modification sites of enzymes [9]. Recent studies have shown that PTMs are related to the pathogenesis of cardiovascular system [10]. Further study on the locus and effect of PTMs could be helpful to further elucidate the mechanism of CVD.

Therefore, this review aims to summarize the emerging roles of various PTMs in cardiovascular disease, discussing
how PTMs affect the pathogenesis of CVD and provide future perspectives on CVD research.

2. The Common Types of PTMs in CVD

The common modification types of proteins in CVD mainly include acetylation, phosphorylation, succinylation, O-GlcNAcylation, methylation, ubiquitination, SUMOylation, glutathionylation, tyrosine nitration, and propionylation (Table 1). There may be a crosstalk among various PTMs in CVD. Notably, succinylation is also involved in the CVD, which is closely relative with metabolism in the cardiomyocyte [11]. Additionally, acetylation, which is another common type of PTMs, has been proved to participate in the regulation of enzyme activity [12]. The various types of PTMs and their modification sites have been described in detail in the previously published review, which we will not repeat here [13–15].

Various PTMs play important roles in CVD. Here, we take SUMOylation and phosphorylation as examples to illustrate the critical roles of PTMs in CVD. Phosphorylation affects the activity of protein, while SUMOylation may affect the production of protein quantity. Protein phosphorylation, a reversible PTMs process, is a PTM regulated by kinase and phosphatase and regulates protein activity and protein interaction through substrate phosphorylation and dephosphorylation [16]. Protein phosphorylation is a key regulator of nitric oxide synthase (eNOS) activity in endothelial cells. Phosphorylation at Tyr81 and Tyr657 regulates NO production by regulating the activity of eNOS. Notably, eNOS stabilizes the vascular environment with NO, and low doses of NO can maintain vascular tension. Therefore, phosphorylation of eNOS plays an important role in the dynamic regulation of eNOS activity in CVD [17]. Then, AKT is activated in cardiomyocytes by phosphorylation of T308 and S473 [18], mediates cellular metabolism, and plays a cardioprotective role in the heart. For example, Akt1 activity regulates cardiac systolic function and coronary angiogenesis and protects the heart from damage caused by pathological cardiac hypertrophy by maintaining physiologival homeostasis [19]. In addition, oxidative phosphorylation (OXPHOS) is involved in the regulation of mitochondrial energy generation, and glutaredoxin-2 (Grx2) regulates the function of cardiac mitochondrial protein by catalyzing deglutathionylation [20, 21]. For instance, the study performed by Mailloux et al. found that Grx2-deficient mice had lower glutathionylation level, glucose intake, ROS production, and decreased mitochondrial complex I activity [21]. These changes can be reversed by glutathione (GSH) supplementation, restoring mitochondrial ATP production and reducing ROS production, which may be a novel treatment for redox damage.

In addition, SUMOylation is a reversible small ubiquitin-associated modification that binds lysine residues in proteins at the protein level. DeSUMOylation is performed by the SENP family [22]. Ubc9-mediated SUMOylation plays an important role in cardiac development, regulating the SUMO pathway and reducing the incidence of heart disease by increasing autophagy flux [23]. G protein signal transduction regulator 12 (RGS12) inactivates the AKT/mTOR signaling pathway by upregulating phosphorylation and SUMOylation of PTEN [24]. In endothelial cells, PPARγ negatively regulates the eNOS-NO pathway through SUMOylation and exacerbates endothelial dysfunction [25]. Therefore, the imbalance of SUMOylation and deSUMOylation is associated with the development of CVD.

What is more, protein glutathionylation is a reversible oxidative modification in which a mixed disulphide is formed between glutathione and protein mercaptan to regulate protein activity. Glutathionylation is involved in the pathogenesis of CVD by regulating the redox signaling pathway, playing an increasingly important role in the regulation of cardiovascular function [26].

3. PTMs in Heart Development

Congenital heart disease (CHD) is a genetically regulated congenital structural abnormality of the heart that is most common in neonates and before birth [27]. CHD, which accounts for about 1% of newborns, is more common in miscarriages and stillbirths [28]. Interactions between different types of proteins are the basis of normal heart development (Figure 1), and acetylation plays an important role in regulating embryonic heart development and myocardial cell energy metabolism [29]. The study conducted by Fukushima et al. reported that myocardial acetylation increases after birth, and cardiac hypertrophy reduces the acetylation level and delays the maturation of cardiac fatty acid oxidation [30]. In addition, succinylation is associated with neonatal cardiometabolism. Therefore, amino acid acetylation and succinylation have important effects on neonatal cardiac energy metabolism [31].

SUMOylation plays an important role in the development of a normal heart. Wang et al. reported that SUMO1 deficiency can cause cardiac septal dysplasia and congenital heart disease [32]. SUMOylation of GATA4, GATA5, and GATA6 regulates cardiac value and expression [33]. SUMOylation of GATA4 activates the modification of SUMO-1 at K445 and regulates the expression of cardiac protein in cardiogenic genes [34]. Furthermore, the SUMOylation of GATA5 in K324 and K360 restores abnormal expression of early cardiac differentiation and development [35]. The study conducted by Chen et al. found that the SUMO1 of GATA6 was translated into a SUMOylation at the K12 site, which regulated cardiac development through transcription [36]. These results suggest that the SUMOylation of GATA4, GATA5, and GATA6 may serve as therapeutic targets for early cardiac development. In addition, SUMOylation plays a key role in embryonic heart morphological development. SUMOylation promotes Nkx2.5 transcriptional activity [37]. SUMOylation enhances the activity of Nkx2.5 by covalency binding to the lysine residues 51, and Nkx2.5 mutations are involved in CHD through the abnormal SUMOylation [38]. Additionally, SENP2 interacts with Nkx2.5, and SENP2 overexpression promotes the severity of CHDs in the hearts of Nkx2.5 haploidy deficient mice [39]. Therefore, SUMOylation plays irreplaceable roles in the process of heart development.
| Modification       | Chemical structure | Modified residue | Addition                        | Removal                          | Type of CVD                                      |
|-------------------|--------------------|------------------|---------------------------------|---------------------------------|-------------------------------------------------|
| Acetylation       | ![Acetylation](image) | Lysine, N-termini | Enzymatic and nonenzymatic      | Enzymatic (HDACs and SIRT1-7)   | Myocardial hypertrophy, HF, I/R, hypertension, atherosclerosis |
| Phosphorylation   | ![Phosphorylation](image) | Serine, threonine, tyrosine | Enzymatic (kinase, phosphatase) | Enzymatic (kinase, phosphotransferase) | HF, I/R, hypertension, atherosclerosis |
| Succinylation     | ![Succinylation](image) | Lysine           | Enzymatic and nonenzymatic      | Enzymatic (SIRT5)               | I/R, AF, myocardial hypertrophy                  |
| O-GlcNAcylation   | ![O-GlcNAcylation](image) | Serine, threonine, cysteine | Enzymatic (OGT)                | Enzymatic (OGA)                 | HF, hypertension, myocardial hypertrophy         |
| Methylation       | ![Methylation](image) | Lysine, N-termini | Enzymatic (methyltransferases)   | Enzymatic (demethylases and KDMs) | HF, myocardial hypertrophy                       |
| Ubiquitination    | ![Ubiquitination](image) | Lysine           | Enzymatic (E1/E2/E3)            | Enzymatic (deubiquitinating enzymes) | HF                                               |
| SUMOylation       | ![SUMOylation](image) | Lysine           | Enzymatic (E1/E2/E3)            | Enzymatic (deSUMOylation enzyme) | Myocardial hypertrophy, HF, I/R, MI, hypertension, atherosclerosis, cardiac remodeling |
| Glutathionylation | ![Glutathionylation](image) | Cysteine         | Glutenoxyredox protein          | Glutaredoxin-1                  | Myocardial hypertrophy, I/R, MI, hypertension, atherosclerosis, cardiac remodeling |
| Tyrosine nitration| ![Tyrosine nitration](image) | Tyrosine         | Structure change                 | Nonenzymatic                    | I/R, HF, atherosclerosis                         |
In addition to SUMOylation, more and more recent studies have focused on glutathionylation, highlighting the critical role of SUMOylation in physiological conditions. Protein glutathionylation takes part in maintaining normal physiological functions of the cells and the body. For example, glutaredoxin-1 (Glrx) is an enzyme that can remove S-glutathionylation of proteins. Glrx reverses S-glutathionylation of GAPDH and plays a role in the key step of apoptosis signal transduction, thus participating in regulating apoptosis [40]. Moreover, eNOS is regulated by direct S-glutathionylation in the endothelial cells [41]. NO reacts with superoxide to form peroxynitrite, which activates S-glutathionylation in Cys674 to regulate SERCA2 activity and vascular smooth muscle function [42]. Nitroso glutathione (GSNO) reduces SIRT-1 activity by S-glutathionylation [43]. Consequently, S-glutathionylation plays a role in maintaining the physiological functions of endothelial cells and smooth muscle cells.

Table 1: Continued.

| Modification | Chemical structure | Modified residue | Addition | Removal | Type of CVD |
|--------------|--------------------|-----------------|----------|--------|-------------|
| Propionylation | ![Chemical Structure](image) | Lysine | Enzymatic | Enzymatic (SIRT1-3) | MI, atherosclerosis |

![Diagram of posttranslational modifications in heart development](image)

Figure 1: The role of posttranslational modifications in the process of heart development.

4. Role of PTMs in CVD

4.1. Role of PTMs in Myocardial Hypertrophy. Cardiac hypertrophy is a process in which the heart maladjustment to various stimuli can progress to marked heart failure [44]. Acetylation is involved in the pathophysiology of cardiac hypertrophy (Figure 2). SIRT3 and SIRT1 acetylations influence the physiological and pathological states of the myocardium. Enhanced inflammation caused by ROS accumulation plays an important role in the progression of cardiovascular disease, and SIRT3 regulates mitochondrial function by regulating ROS metabolism and maintains normal cardiac function [45]. Similarly, the study carried out by Pillai et al. confirmed that ROS signal is a key signal of cardiac hypertrophy. Increased mitochondrial SIRT3 activity is associated with reduced acetylation of SIRT3 substrates, MnSOD, and oligomycin-sensitive endogenic protein (OSCP), which reduced ROS synthesis by increasing mitochondrial oxygen consumption rate, thereby preventing
cardiac hypertrophy [46]. In addition, SIRT3 deficiency leads to acetylation of long-chain acyl-CoA dehydrogenase (LCAD) at lysine 42, resulting in disrupted fatty acid oxidation including reduced ATP production [47]. SIRT3 reduces intracardiac hypertrophy-related lipid accumulation and alleviates the progression of cardiac hypertrophy by deacetylation of LCAD [48]. In addition, SIRT1 is also involved in cardiac hypertrophy, and deacetylated protein kinase C-δ (PKC-δ) can improve cardiac hypertrophy [49]. Moreover, SIRT7 promotes the deacetylation of GATA4 to play an antihypertrophy role [50]. The study performed by Li et al. demonstrated that fibroblast growth factor 21 (FGF21) reduces angiotensin II-induced cardiac hypertrophy by increasing SIRT1 deacetylase activity [51].

Furthermore, O-GlcNAcylation has been implicated in the development of cardiac hypertrophy. Previous studies have shown that O-GlcNAcylation modification increases with the progression of cardiac hypertrophy, and O-GlcNAcylation promotes cardiac compensatory function during early cardiac hypertrophy [52]. Moreover, it has been observed that O-GlcNAcylation modulates vascular dysfunction due to intermittent hypoxia by regulating the MAPK pathway [53]. Therefore, O-GlcNAcylation plays a regulatory role in pathological hypertrophy.

Additionally, SUMOylation contributes to the regulation of oxidative stress response and improvement of cardiac function. SUMO-1 reduced oxidative stress markers in cardiac hypertrophy, and SERCA2a modified with SUMO-1 prevented the occurrence of cardiac hypertrophy [54]. Moreover, SUMO-1 activates the transcriptional activity of shock transcription factor 2 (HSF2) and induces cardiac hypertrophy in hypertensive rats through IGF-IIR-mediated signaling pathway [55]. SUMO-2 activates calcineurin-(Cn-) NFAT signaling and promotes cardiac hypertrophy [56]. Furthermore, the study performed by Wang et al. showed that the SUMOylation of C/EBPβ K134 contributes to PARP1-induced cardiac hyperplasia by reducing the stability of C/EBPβ [57].

Succinylation maintains cardiac metabolism and function under stressful conditions during cardiac hypertrophy. The study conducted by Hershberger et al. showed that SIRT5 participates in the deacetylation of protein substrates in cellular oxidative metabolism, maintaining cardiac oxidative metabolism under stress overload caused by cardiac hypertrophy to maintain mitochondrial energy production [58]. Similarly, the study carried out by Wang et al. demonstrated in SIRT5 KO mouse model that the succinylation level of oxidative metabolic protein increased and continued to accumulate after birth, inducing cardiac hypertrophy [59].

The 5-glutathionylation participates in cardiac hypertrophy through oxidative stress. For example, the study performed by Pimentel et al. demonstrated that mechanical strain stimulates the Raf/MEK/ERK pathway, which was dependent on Ras s-glutathionylation, and, therefore, participates in myocyte growth signal transduction to regulate protein synthesis in cardiac hypertrophy [60]. In addition, glutathionylation was significantly increased in Grx2 knockout mice, leading to myocardial hypertrophy by reducing myocardial ATP production [21].

**Figure 2:** Specific modification sites of types of posttranslational modification in myocardial hypertrophy.
Methylation has also been implicated in the development of heart dysfunction. The study conducted by Jeong et al. suggested that PRMT1 is methylated at ATF4 of arginine 239 and regulates the protein stability of ATF4 in endoplasmic reticulum stress of cardiomyocytes and plays a protective role in cardiomyocytes [61]. In cardiomyocytes, PRMT5 symmetrically dimethylates HoxA9 and inhibits HoxA9 expression, preventing binding to promoters and protecting cardiomyocytes from cardiac hypertrophy [62]. PRMT5 protects cardiomyocytes from hypertrophy by reducing GATA4 transcriptional activity, and activation of PRMT5 may be a potential therapeutic target for cardiac hypertrophy [63]. Accumulation of methylated arginine metabolites can cause left ventricular diastolic dysfunction, which can aggravate myocardial hypertrophy injury. Therefore, arginine methylated derivatives, such as ADMA, can be used as markers to predict disease progression and prognosis [64]. However, more predictive targets for the disease need to be studied. Therefore, methylation is a potential target for treating future diseases.

In summary, acetylation, O-GlcNAcylation, SUMOylation, methylation, and glutathionylation are involved in the pathogenesis and progression of cardiac hypertrophy in response to oxidative stress, signaling pathways, and metabolites, thereby affecting normal cardiac function. However, the response levels of the new PTMs require further studies.

4.2. Role of PTMs in Acute Myocardial Infarction. Myocardial reperfusion injury is the injury during blood restoration after thrombolytic therapy after acute myocardial infarction, including myocardial tissue injury and dysfunction caused by reperfusion [65]. Epidemiology shows more than 800,000 people develop acute myocardial infarction each year, 27% of whom die, and myocardial infarction remains the leading cause of death globally [66].

Mitochondrial dysfunction is an important cause of myocardial reperfusion (I/R) injury. Clinical evidence suggests that patients with diabetes are more prone to cardiac I/R injury due to imbalance of antioxidant mechanism. The succinylation of SIRT5 is involved in the progression of I/R injury [65]. The study performed by Boylston et al. illustrated that succinyl protein accumulates in cardiometabolic pathway and increases the severity of myocardial infarction through in vivo study of SIRT5 knockout mice after ischemia-reperfusion [11]. Moreover, it has been reported that SIRT5-deficient adipose-derived mesenchymal stem cells (ADMSCs) have increased protein succinylation, reduced mitochondrial respiration, and altered glucose metabolism patterns, thereby promoting vascular proliferation [67]. Succinylation of SIRT5 is a potential therapeutic target in I/R injury.

Phosphorylation is involved in the early activation of I/R damage. The study carried out Bibili and others reported that PYK2 is a key regulator of eNOS function in myocardial infarction. PYK2 activates phosphorylation of Y402 and eNOS activates phosphorylation of S1176. PYK2 leads to eNOS phosphorylation of Y656 induced by ischemia-reperfusion and regulates eNOS function in myocardial infarction [68]. Therefore, PYK2 may become a new therapeutic target for myocardial ischemia-reperfusion in the future.

Acetylation regulates I/R-impaired cardiac function. The study conducted by Leng et al. proposed that inhibition of HDAC6 modulates the acetylation of Prdx1 at K197, reducing ROS production and the severity of myocardial infarction and protecting against I/R injury [69]. Progressive loss of cardiomyocytes due to p53 is mediated apoptosis in myocardial infarction. In myocardial infarcted hearts, Lys118 residues of p53 are severely acetylated. However, it was completely reversed in the oxygenated heart, inhibiting Lys118 acetylation promoted the production of NOS3 and promoted the survival activity of p53, thus reducing myocardial infarction and protecting cardiac function [70]. Additionally, mangiferin increased FOXO3a deacetylation by upregulating SIRT1 in myocardial infarction, thereby preventing apoptosis and significantly reducing the size of myocardial infarction [71].

SUMOylation also implicates in AMI. PIAS1 is the specific E3 ligase of PPARy SUMOylation. After I/R injury, the levels of PIAS1 and PPARy SUMOylation decreased significantly, and apoptosis and inflammation increased, which exacerbated the severity of I/R injury [72]. Moreover, SENP2 deficiency increases Akt SUMOylation and Akt kinase activity, promoting cardiac regeneration [73]. Destruction of the SUMOylation of HDAC4 results in the accumulation of HDAC4 in cardiomyocytes, leading to a significant reduction in ROS [74]. Therefore, SUMOylation of HDAC4 could be a potential therapeutic target for I/R injury. Farnesoid X receptor (FXR) regulates cardiomyocyte apoptosis. Gao et al. demonstrated that reduced FXR SUMOylation promotes apoptosis and exacerbates cardiac injury by activating mitochondrial apoptosis pathway and autophagy dysfunction [75].

The role of glutathionylation in ischemic cardiomyopathy has also been reported. Glutathionylation of mouse cardiac SERCA protein leads to increased Ca2+ uptake and modulates myocardial contractility [76]. Actin glutathionylation promotes decreased systolic capacity during myocardial ischemia. Glutathionylation in mitochondrial complex I increases cytochrome C release, induces survival signals, promotes infarct size and cardiac dysfunction, and is regulated by glutathione de glutathione [77]. I/R injury leads to de glutathione in mitochondrial complex II and decreases its activity [78]. Therefore, glutathionylation of the proteins may be a potential therapeutic target for ischemic cardiomyopathy.

Overall, these findings indicated that succinylation, phosphorylation, SUMOylation, acetylation, and glutathionylation are involved in the formation and progression of I/R injury and play important roles in the regulation of cardiac repair.

4.3. Role of PTMs in Heart Failure. Heart failure (HF) is a pathological process in which cardiac systolic or diastolic dysfunction results in arterial hypoperfusion and impaired circulation [79]. According to statistics, there are about 37.7 million patients with heart failure worldwide, and the incidence of heart failure is still on the rise [80]. The high morbidity and mortality of heart failure have become a leading cause of hospitalization among adults and the elderly [80].
HF patients were divided into three types based on left ventricular ejection fraction (EF): reduced EF group (EF < 40%), borderline EF (40% ≤ EF < 50%), and the EF retention group (EF ≥ 50%). The decreased EF group suggested insufficient cardiac output, while the retained EF group suggested relatively normal left ventricular contractility [81].

GlcNAcylation plays an important role in heart failure. The O-GlcNAcylation levels depend on the activity of O-GlcNAc transferase and O-Glcnacase, and excessive O-GlcNAcylation can lead to cardiomyopathy and heart failure due to energy deficiency [82]. The reduction of O-GlcNAcylation may have a protective effect on overload induced pathological remodeling and heart failure. Midbrain natriuretic peptide prohormone (proBNP) levels are elevated, and Thr48 and 71 O-GlcNAcylate promote the secretion of proBNP in HF patients. GalNA-transferase (GALNT) 1 and 2 promote the secretion of human proBNP (prohormone proBNP) in HF patients. Galna-transferase (GALNT) 1 and 2 promote the secretion of proBNP in HF patients. Galna-transferase (GALNT) 1 and 2 promote the secretion of proBNP in HF patients. Deglycosylated NT-proBNP level may be an important marker of heart failure [83].

Phosphorylation regulates energy metabolism in heart failure. Protein phosphorylation regulates SERCA2a activity and regulates myocardial diastolic and contractile processes. Camp or cGMP dependent protein kinases are phosphorylated at Ser16, while Ca<sup>2+</sup>-calmodulin-dependent protein kinases (CaMKII) are phosphorylated at Thr17, which triggers SR Ca<sup>2+</sup> uptake and SR Ca<sup>2+</sup> load to regulate cardiac function in heart failure [85]. The study carried out by Cope-land et al. confirmed the phosphorylation of MYBP- C plays an important role in regulating myocardial systolic function. In vitro studies have confirmed that MYBP-C can be phosphorylated at ser273, 282, 302, and 307. There are still several phosphorylation sites that need more in vivo studies to prove [86]. AMPKα2 enhances mitochondrial autophagy by phosphorylating PINK1 at Ser495, preventing further aggravation of heart failure [87]. Inhibition of PKCζ reduces the formation of protein aggregates in cardiomyocytes; Bouvet et al. reported that phosphorylation activation of PKCζ in heart failure leads to dysfunction of the proteolysis system, thereby exacerbating cardiac dysfunction [88].

Changes in acetylation status may play a role in the pathophysiology of heart failure. Gorski et al. demonstrated SIRT1 regulates cardiac SERCA2a activity through acetylation at site K492, and this site can activate SIRT1 deacetylation to restore SERCA2a activity through pharmacological action, thus playing an important role in cardiac homeostasis regulation. This site may be a new strategy for the treatment of heart failure [89]. SIRT1 alleviates HF by increasing the deacetylation level of p53 and inhibiting myocardial cell apoptosis [90]. In mitochondria, both fatty acid oxidation and complex I deficiency increase protein acetylation, exacerbating cardiac dysfunction and heart failure [91]. In the process of mitochondrial metabolic stress, SENP1 loss leads to the hypersumoylation of SIRT3 and the hyperacetylation of mitochondrial proteins, and the acetylation and SUMOylation crosstalk jointly regulate SIRT3 activation and mitochondrial metabolism [92]. Transforming growth factor β1 (TGF-β1) mediates the transformation of fibroblasts into myofibroblasts and increases extracellular matrix synthesis. SIRT3 deficiency leads to TGF-β1 expression and glycogen synthase kinase 3β (GSK3β) overacetylation at Lys15, leading to tissue fibrosis. SIRT3 deacetylates and activates GSK3β, thereby blocking TGF-β1 signal transduction and tissue fibrosis [93]. Therefore, SIRT3 is a key regulator of cardiac energy metabolism and a potential therapeutic target. The study performed by Renguet et al. showed that the acetylation of leucine inhibits cardiac glucose uptake and dysregulated glucose homeostasis [94]. Further studies are needed to regulate the acetylation of mitochondrial proteins by more metabolites related to oxidative metabolic pathways.

The SUMOylation of SERCA2a also plays an important role in HF. SERCA2a levels decrease in HF and regulate intracellular calcium homeostasis, which has potential clinical application value [95]. Therefore, SERCA2a is SUMOylated at Lys 480 and 585 and regulates myocardial contractility in heart failure [96]. Additionally, the SUMOylation of SERCA2a has also been reported in the treatment of HF, for example, simultaneous transfection of SUMO1 and SERCA2a with adeno-associated virus vectors also increased SERCA2a expression and function [97]. Therefore, SENP5 is the only SENP upregulated in human heart failure. The SUMOylation of Drp1 leads to increased mitochondrial swelling and fission, triggering apoptosis, leading to heart failure and cardiomyopathy [98].

Overall, these findings indicated that phosphorylation, acetylation, O-GlcNAcylation, and SUMOylation are involved in the pathogenesis of HF and the regulation of heart remodeling. However, further studies are necessary to elucidate the crosstalk between PTMs in treating HF.

4.4. Role of PTMs in Hypertension. Hypertension is a multifactorial disease involving the heart, kidney, and other systems [99], whose vascular damage causes serious damage to the heart and is the main risk factor for cardiovascular diseases. Hypertension was the fourth leading cause of cardiovascular diseases in the world in 2015, accounting for one-third of global deaths [100]. Vascular dysfunction is an important pathophysiological mechanism of hypertension and endothelial cell dysfunction throughout the development of hypertension [101].

Phosphorylation is involved in the development of hypertension (Figure 3). WWP2 regulates hypertensive vascular disease by regulating SIRT1-STAT3 complex. In vascular smooth muscle cells, WWP2 and SIRT1-STAT3 complexes promote the acetylation of STAT3-K685 and phosphorylation of STAT3-Y705 by inhibiting the interaction between SIRT1 and STAT3 and increase the severity of hypertensive lesions [102]. The study carried out by Boguslavskyi et al. illustrated that phospholemman is hypophosphorylated in a mouse model of aging that induces senescent essential hypertension. Phosphorylation of phospholemman therefore regulates vascular tone and hypertension [103]. Anihypertensive drugs can inhibit the phosphorylation of epidermal growth factor receptor (EGFR) of Y1068 in vascular smooth muscle cells. Therefore, EGFR inhibition is a treatment for cardiovascular diseases such as hypertension and atherosclerosis [104].
Acetylation-mediated mitochondrial metabolism is involved in the development of hypertension. The normal morphology of mitochondria is regulated by the balance of fusion and fission. The study performed by Samant et al. reported that the acetylation of the mitochondrial fusion protein OPA1 at lysine 926 and 931 occurs. Excessive acetylation of OPA1 under pathological stress reduces the GTPase activity of OPA1. Mitochondrial deacetylase SIRT3 can deacetylate OPA1, improve its GTPase activity, and restore mitochondrial function [105]. Loss of SIRT3 promotes endothelial dysfunction, oxidative stress, and vascular hypertrophy in essential hypertension, leading to cardiac dysfunction [106]. Cyclophilic protein A (CyPA) increases VSMC and endothelial cell production by acetylation of lysine K82 and K125 [107]. Similarly, SIRT3 loss leads to high acetylation of mitochondrial SOD2, leading to endothelial dysfunction, hypertension, and other cardiovascular diseases in mice [106].

Moreover, the level of O-GlcNAcylation affects vascular function. O-GlcNAcylation regulates vascular reactivity under normal physiological conditions. Dysvascular dilation is associated with elevated levels of O-GlcNAcylation protein in hypertensive patients [108]. However, the acute increase of the O-GlcNAcylation of the protein inhibits the expression of iNOS and prevents vascular dysfunction induced by TNF-α, thereby protecting the heart and blood vessels [109]. In blood vessels, eNOS and PKC are targets of O-GlcNAcylation in the vascular system [110]. The study carried out by Nagy et al. demonstrated that increased O-GlcNAcylation inhibited angiotensin II-induced Ca^2+ levels in ventricular myocytes [111]. Endothelin-1 increases O-GlcNAcylation levels and plays a role in vascular changes in hypertension-related vascular dysfunction [112].

Furthermore, SUMOylation has been also been implicated in hypertension. SENP3 inhibits proteasome-dependent degradation through the deSUMOylation of β-catenin. Mediate vascular remodeling and regulate vascular homeostasis [113]. Activating transcription factor 3 (ATF3) is SUMOylation of lysine 42 via SUMO1 and is involved in Ang II-induced endothelial dysfunction [114]. Therefore, SUMO2 plays an important role in maintaining normal endothelium-dependent vascular function [115]. The study carried out by Kim et al. reported that overexpression of SUMO2 would increase oxidative stress, damage vascular endothelial function, and increase the incidence of hypertension [116]. SUMO2 enhancement can lead to apoptosis, disrupt vascular physiological state, and lead to endothelial dysfunction. Therefore, an imbalance in SUMOylation could lead to a pathological state.

In hypertensive vessels, increased eNOS S-glutathionylation in endothelial cells is positively associated with impaired endothelium-dependent vasodilation, which is reversible and can be reversed with thiol-specific reducing agents [117]. S-glutathionylation of small GTPase Ras plays a role through Ser mutants that increase the muscle tone of AngII-induced smooth muscle cells and regulate hypertension [118]. Thus, S-glutathionylation regulates the progression of hypertension by acting on endothelial and smooth muscle cells.

Overall, these findings confirmed that acetylation, phosphorylation, O-GlcNAcylation, SUMOylation, and S-glutathionylation are involved in the pathogenesis of hypertension.

4.5. Role of PTMs in Atherosclerosis. Atherosclerosis is characterized by the formation of lipid plaques in the arteries.
Acetylation has been implicated in atherosclerosis development. In a case-control study of 342 patients, An et al. reported that glycoprotein acetylation level was positively correlated with the incidence of heart disease [122]. Thiazolidinedione (TZDs) is a peroxisome proliferator activated receptor γ (PPARγ) agonist, which is an antiatherosclerosis insulin sensitizer. The study conducted by Liu et al. illustrated that PPARγ was deacetylated at K268 and K293 and inhibited the expression of atherosclerotic factors through endothelium-dependent vasodilatation, thus exerting an antiatherosclerosis effect [123]. Aspirin acts as an antiplatelet agent by preventing protein aggregation through acetylation [124]. Hyperglycemia has a direct effect on the acetylation of COX-1 at Ser529, and aspirin can inhibit its acetylation and play a protective role in diabetes-induced cardiovascular disease [125].

Tyrosine nitration of proteins increases the likelihood of atherosclerosis. The study performed by Peluffo and Radi suggested that nitrotyrosine was a new independent marker of cardiovascular disease [126]. The study carried out by DiDonato et al. illustrated that nitration of ApoA-I at Tyr166 in atherosclerotic arterial wall leads to vascular selective dysfunction [127]. Furthermore, nitrification of PKG-1α at tyrosine 247 and 425 and nitrification of tyrosine 247 can reduce the affinity of PKG-1α to cGMP and regulate the proliferation and differentiation of atherosclerosis smooth muscle cells [128].

Phosphorylation is essential for atherosclerosis. Endothelial barrier dysfunction is one of the causes of atherosclerosis. The study conducted by Starosta et al. reported that high OXPAc concentrations promote Src and ROS-dependent phosphorylation of VE-cadherin Tyr658 and Tyr731, leading to endothelial barrier dysfunction [129]. AMPK phosphorylates YAP at sites 94, 61, and 793 on serine, where Ser61 and Ser793 inhibit YAP activity, regulate cell metabolism and function, and participate in antcardiovascular disease effects [130]. PKC activation is required for Ang II-induced migration of vascular smooth muscle cells (VSMCs). PKC is rapidly phosphorylated by Ang II at Tyr311 and contributes to the development of Ang II-induced cardiovascular disease by participating in Akt activation and Ang II-induced VSMC hypertrophy [131]. The study performed by Wang et al. showed that coal-derived PM2.5 can promote the phosphorylation of MAPK signaling pathway-related proteins and promote the formation of atherosclerosis [132].

Atherosclerosis is associated with S-glutathionylation. The previous study showed that serum S-glutathionylation levels were positively correlated with the severity of atherosclerotic disease and could be used as a predictive marker of arteriosclerotic obliterans [133]. Cell oxidized low-density lipoprotein (OxLDL) is a major risk factor for atherosclerosis. OxLDL promotes glutathione formation of related proteins glutathionylation and ROS and promotes cell death [134]. Angiotensin II regulates redox reactions by forming and activating S-glutathionylation of Ras via Cys118, thereby inducing protein synthesis in atherosclerosis [118]. In addition, p21Ras is modified by S-glutathionylation at Cys118 to regulate growth factor signaling in the vascular system. S-glutathionylation of IP3 receptor regulates Ca2+ storage and Ca2+ release and influences the Ca2+ homeostasis of endothelial cells [135]. However, the mechanism of S-glutathionylation in atherosclerosis has not been fully elucidated and needs further study.

Furthermore, SUMOylation is involved in endothelial dysfunction, dyslipidemia, and VSMC proliferation in atherosclerosis. SUMOylation regulates the release and expression of inflammatory factors by modifying NF-κB and TLR. GATA2 was also modified to regulate the expression of endothelial cell adhesion molecules and jointly regulate the inflammatory progression of atherosclerosis [136]. ERK5 is an anti-inflammatory cytokine, and SUMOylation of ERK5 contributes to endothelial dysfunction by inhibiting the expression of nitric oxide synthase in endothelial cells, leading to atherosclerosis [137]. However, overexpression of p53 and ERK5 SUMOylation in endothelial cells protects atherosclerosis by inhibiting apoptosis and adhesion molecules. SENP2 regulates p53 and ERK5 SUMOylation and is involved in endothelial atherosclerosis [138]. SUMOylation of NLRP3 inhibits the activation of inflammasome. SENP7 deficiency inhibits the SUMOylation of NLRP3, which activates caspase-1 and releases IL-1β, and exacerbates the inflammatory damage of atherosclerosis [139]. In addition, the SUMOylation of PARα at K185 is closely associated with atherosclerotic dyslipidemia [140]. Therefore, SUMO and SUMOylation play a crucial role in atherosclerosis, and SUMOylation of ERK5, SENP2, and GATA2 may be potential therapeutic targets for atherosclerosis.

Overall, the current studies have proved that acetylation, phosphorylation, tyrosine nitration, SUMOylation, and S-glutathionylation are involved in the development of atherosclerosis, providing potential targets for future clinical research.

5. Future Development Direction

Recent advances in mass spectrometry and omics techniques have facilitated studies on PTMs and crosstalk between PTMs of proteins. PTMs not only affect the progression of CVDs but also regulate CVD-related syndromes, such as insulin sensitivity and diabetic cardiomyopathy. For example, the study carried out by Choi et al. demonstrated that PTMs of PPARγ regulate PPARγ activity or stability, thereby optimizing PPARγ activity and reducing insulin resistance [141], which could improve the treatment of metabolic syndromes and atherosclerotic vascular diseases. Moreover, SUMOylation is involved in some kinase pathways that regulate apoptosis in diabetic cardiomyopathy [142]. The study conducted by Heo et al. demonstrated that SUMOylation regulates ERK5 by inhibiting ERK5’s transcriptional capacity [138], thereby regulating apoptosis. Furthermore, Tabrez et al. used an untargeted metabonomics
approach to identify metabolites that may be associated with CVD [143], indicating the importance of metabolomics in CVD treatment. However, further research is needed to determine the relationship between metabolites and the pathogenesis of CVD. The study performed by Sadhukhan et al. illustrated that succinylation and SIRT5 are important regulators of cardiac function, using metabolomics with proteomics techniques [144].

Mass spectrometry provides a method to further investigate the pathogenesis of metabolite-associated PTMs in cardiovascular diseases. Additionally, sequencing technology and the cosequencing of RNA and protein levels have improved the understanding of the role of PTMs in CVDs. For example, machine learning-based prediction of protein modification sites, such as acetylation, succinylation, and ubiquitination, has emerged as predictive tools of CVDs [145]. Although studies on PTMs have increased recently, the role of PTMs in the pathogenesis of atherosclerosis in CVD requires further studies.

Furthermore, combination of proteomics and precision medicine can promote the identification of candidate biomarkers for clinical diagnosis, prognosis, monitoring, and personalized patient medication design and delivery, which can promote CVD treatment. For example, the study performed by Meng et al. illustrated the use of the target space of PTM protein isomers to inspire new directions in drug design by precisely targeting PTM protein isomers or complexes that are highly related to biological functions [146]. This new approach will further promote personalized therapy for precise treatment of PTM subtypes.

Several studies have identified the role of PTMs of protein in CVDs, and specific-related modification sites may become new biomarkers for predicting cardiovascular disease risk. The study carried out by Kuwahara et al. identified that deglycosylated NTproBNP as a significant new marker of heart failure [84]. Additionally, kinase-related drug development, such as the mitochondrial membrane protein branch α-ketoate dehydrogenase (BCKD) complex, which regulates mitochondrial oxidative metabolism through BCKD kinase modification sites, could be a potential therapeutic target for CVD. HDAC inhibitors can increase lysine acetylation, and HDAC inhibition therapy could be potential treatment strategy for patients with heart failure [147]. PTMs are based on basic research on clinical guidance methods to provide a theoretical basis for clinical diagnosis, prognosis, and treatment of CVD.

Currently, the development and clinical trials of therapeutic drugs targeting PTMs mainly focus on phosphorylation. For example, alamandine is a peptide of the renin-angiotensin system (RAS) that protects the cardiovascular system and improves stress-overload induced cardiac remodeling by reducing ERK1/2 phosphorylation and increasing AMPKα phosphorylation [148]. Alamandine holds promise as a cardiovascular treatment in the future. In addition, immunosuppressant applications are being developed to enhance the monitoring of therapeutic agents and individual differences through pharmacodynamics (PD) monitoring by directly measuring the activity of target enzymes and phosphorylation. The study conducted by Budde et al. determined the activity of mycophenolate acid target enzyme inosin-5′-monophosphate dehydrogenase (IMPDH) and the phosphorylation of rapamycin (mTOR) target molecule and found that the mTOR pathway is an appropriate target for individualized PD monitoring of sirolimus and everolimus after organ transplantation [149]. Moreover, studies on mitochondrial drug targets in CVD mainly focus on mitochondrial ATP-dependent potassium channel. Diazoxide activates mitochondrial ATP-dependent potassium channel phosphorylation by stimulating PKC, promotes channel opening, and plays a protective role in myocardial ischemia-reperfusion injury [150]. However, the multicenter clinical studies are needed to further prove the clinical effectiveness. More potential therapeutic targets require pharmacodynamic detection and clinical trials to prove their potential clinical therapeutic value.

6. Conclusion

PTMs is not only involved in protein stability, activity, subcellular localization, and interaction but also plays an important role in regulating protein expression under physiological and pathological conditions. PTMs play an important and complex role in regulating the progression of CVD. The protein may have multiple modification sites, and there is crosstalk among various PTMs. PTM sites may be potential drug targets, and the development and utilization of these signaling pathways may become new therapeutic strategies. Therefore, an in-depth understanding of PTMs and its mechanism of crosstalk in the pathological process can provide basic theoretical basis for clinical application. Further research is needed to improve the understanding of CVD in young adults and treatment strategies. Therefore, future work on the involvement PTMs in CVD might include the following:

(1) The specific mechanism of SIRT5 as a regulatory factor of CVD in heart development and the role of succinylation in heart development

(2) Further studies on the cytodynamics of O-GlcNAC modification, and the signaling pathway and mechanism of regulating specific proteins in vascular vessels

(3) The potential clinical application of acetylation in diabetic cardiomyopathy was elucidated by sequencing and metabolite analysis

(4) Further studies on the mechanism and physiological consequences of crosstalk among various PTMs

(5) Clinical studies on the potential therapeutic targets of PTMs in CVD, and precision medicine for clinical diagnosis, prognosis, and treatment of CVD

(6) Further study on the action sites and related mechanisms of various novel modifications in CVD, including crobitoylation, 3-hydroxybutyrylation, and malonylation
Consent

All authors gave their consent for publication.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

Authors’ Contributions

All authors participated in drafting or revising of the manuscript and approved the final manuscript.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (82002021 to Ni Yang, 82102254 to Chun-Feng Liu), Shenyang Science and Technology Major Special Project (no. 2020JH1/10300001 to Tie-Ning Zhang), LiaoNing Province Science and Technology Plan Project (20-205-4-002 to Chun-Feng Liu), and 345 Talent Program of Shengjing Hospital of China Medical University (M0691 to Tie-Ning Zhang).

References

[1] G. D. Flora and M. K. Nayak, “A brief review of cardiovascular diseases, associated risk factors and current treatment regimes,” Current Pharmaceutical Design, vol. 25, no. 38, pp. 4063–4084, 2019.
[2] S. Mendis, S. Davis, and B. Norrving, “Organizational update,” Stroke, vol. 46, no. 5, pp. e121–e122, 2015.
[3] F. G. Fowkes, D. Rudan, I. Rudan et al., “Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis,” The Lancet, vol. 9901, pp. 1329–1340, 2013.
[4] L. J. Laslett, P. Alagona, B. A. Clark et al., “The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology,” Journal of the American College of Cardiology, vol. 60, no. 25, pp. S1–49, 2012.
[5] P. Joseph, D. Leong, M. McKee et al., “Reducing the global burden of cardiovascular disease, part 1,” Circulation Research, vol. 121, no. 6, pp. 677–694, 2017.
[6] N. Krogan, P. Beltrao, P. Bork, N. J. Krogan, and V. Van, “Evolution and functional cross-talk of protein post-translational modifications,” Molecular Systems Biology, vol. 9, no. 1, p. 714, 2013.
[7] R. Wang and G. Wang, “Protein modification and autophagy activation,” Advances in Experimental Medicine and Biology, vol. 1206, pp. 237–259, 2019.
[8] Z. Cui, S. B. Scruggs, J. E. Gilda, P. Ping, and A. V. Gomes, “Regulation of cardiac proteasomes by ubiquitination, SUMOylation, and beyond,” Journal of molecular and cellular cardiology, vol. 71, pp. 32–42, 2014.
[9] M. Kokkinidis, N. M. Glykos, and V. E. Fadouloglou, “Catalytic activity regulation through post-translational modification: the expanding universe of protein diversity,” Advances in Protein Chemistry and Structural Biology, vol. 122, pp. 97–125, 2020.
[10] S. Aggarwal, S. K. Banerjee, N. C. Talukdar, and A. K. Yadav, “Post-translational modification crosstalk and hotspots in sirtuin interactors implicated in cardiovascular diseases,” Frontiers in Genetics, vol. 11, 2020.
[11] J. A. Boylston, J. Sun, Y. Chen, M. Gucek, M. N. Sack, and E. Murphy, “Characterization of the cardiac succinyllome and its role in ischemia-reperfusion injury,” Journal of molecular and cellular cardiology, vol. 88, pp. 73–81, 2015.
[12] T. Narita, B. T. Weintert, and C. Choudhary, “Functions and mechanisms of non-histone protein acetylation,” Nature Reviews. Molecular Cell Biology, vol. 20, no. 3, pp. 156–174, 2019.
[13] H. Aksnes, R. Ree, and T. Arnesen, “Co-translational, post-translational, and non-catalytic roles of N-terminal acetyltransferases,” Molecular Cell, vol. 73, no. 6, pp. 1097–1114, 2019.
[14] L. Chen and A. Kashina, “Post-translational modifications of the protein termini,” Frontiers in Cell and Developmental Biology, vol. 9, 2021.
[15] B. Macak, K. Forchhammer, J. Hardouin, E. Weber-Ban, C. Grangeasse, and I. Mijakovic, “Protein post-translational modifications in bacteria,” Nature Reviews. Microbiology, vol. 17, no. 11, pp. 651–664, 2019.
[16] L. N. Johnson, “The regulation of protein phosphorylation,” Biochemical Society Transactions, vol. 4, pp. 627–641, 2009.
[17] G. K. Kolluru, J. H. Siamwala, and S. Chatterjee, “eNOS phosphorylation in health and disease,” Biochimie, vol. 92, no. 9, pp. 1186–1198, 2010.
[18] I. Yudushkin, “Control of Akt activity and substrate phosphorylation in cells,” IUBMB Life, vol. 72, no. 6, pp. 1115–1125, 2020.
[19] I. Hiers, E. S. Vincent, and J. M. Tavaré, “Akt signalling in health and disease,” Cellular Signalling, vol. 23, no. 10, pp. 1515–1527, 2011.
[20] D. W. Starke, P. B. Chock, and J. J. Mieyal, “Glutathione-thiol radical scavenging and transferase properties of human glutaredoxin (thioltransferase): Potential role in redox signal transduction,” Journal of Biological Chemistry, vol. 17, pp. 14607–14613, 2003.
[21] R. J. Mailloux, J. Y. Xuan, S. McBride et al., “Glutaredoxin-2 Is Required to Control Oxidative Phosphorylation in Cardiac Muscle by Mediating Deglutathionylation Reactions∗,” Journal of Biological Chemistry, vol. 289, no. 21, pp. 14812–14828, 2014.
[22] E. Treuter and J. A. Gustafsson, “Wrestling Rules in Transrepression: As Easy as SUMO-1, -2, -3?,” Molecular cell, vol. 25, no. 2, pp. 178–180, 2007.
[23] M. K. Gupta, P. M. McLendon, J. Gulick, J. James, K. Khalili, and J. Robbins, “UBC9-mediated sumoylation favorably impacts cardiac function in compromised hearts,” Circulation Research, vol. 118, no. 12, pp. 1894–1905, 2016.
[24] C. Fu, G. Yuan, S. T. Yang, D. Zhang, and S. Yang, “RGDS2 represses oral cancer via the phosphorylation and SUMOylation of PTEN,” Journal of Dental Research, vol. 100, no. 5, pp. 522–531, 2021.
[25] W. Yuan, C. Ma, Y. Zhou, M. Wang, G. Zeng, and Q. Huang, “Negative regulation of eNOS-NO signaling by over-SUMOylation of PPARγ contributes to insulin resistance and dysfunction of vascular endothelium in rats,” Vascular Pharmacology, vol. 122-123, p. 106597, 2019.
[26] D. Pimentel, D. J. Haeussler, R. Matsui, J. R. Burgoyne, R. A. Cohen, and M. M. Bachschmid, "Regulation of cell physiology and pathology by protein S-glutathionylation: lessons learned from the cardiovascular system," *Antioxidants & Redox Signaling*, vol. 16, no. 6, pp. 524–542, 2012.

[27] R. Sun, M. Liu, L. Lu, Y. Zheng, and P. Zhang, "Congenital heart disease: causes, diagnosis, symptoms, and treatments," *Cell Biochemistry and Biophysics*, vol. 72, no. 3, pp. 857–860, 2015.

[28] J. I. Hoff, "The role of SUMO-1 in congenital heart disease: incidence and inheritance," *Pediatric Clinics of North America*, vol. 37, no. 1, pp. 25–43, 1990.

[29] M. Yang, Y. Zhang, and J. Ren, "Acetylation in cardiovascular diseases: Molecular mechanisms and clinical implications," vol. 1866, no. 10, Article ID 165836, 2020.

[30] A. Fukushima, L. Zhang, A. Huqi et al., "Acetylation contributes to hypertrophy-caused maturational delay of cardiac energy metabolism," *JCI Insight*, vol. 3, no. 10, 2018.

[31] A. Fukushima, O. A. Alrob, L. Zhang et al., "Acetylation and succinylation contribute to maturational alterations in energy metabolism in the newborn heart," *American Journal of Physiology. Heart and Circulatory Physiology*, vol. 311, no. 2, pp. H347–H363, 2016.

[32] J. Wang, L. Chen, S. Wen et al., "Defective sumoylation pathway directs congenital heart disease," *Birth Defects Research. Part A, Clinical and Molecular Teratology*, vol. 6, pp. 468–476, 2011.

[33] C. Du, X. Chen, Q. Su et al., "The function of SUMOylation and its critical roles in cardiovascular diseases and potential clinical implications," *International Journal of Molecular Sciences*, vol. 22, no. 19, p. 10618, 2021.

[34] J. Wang, A. Li, Z. Wang, X. H. Feng, E. N. Olson, and R. J. Schwartz, "Myocardin sumoylation transactivates cardiogenic genes in pluripotent 10T1/2 fibroblasts," *Molecular and Cellular Biology*, vol. 27, no. 2, pp. 622–632, 2007.

[35] R. Wen, H. Yuan, X. Liu et al., "GATA5 SUMOylation is indispensable for zebrafish cardiac development," *Biochimica et Biophysica Acta - General Subjects*, vol. 1861, no. 7, pp. 1691–1701, 2017.

[36] H. Chen, W. Sun, J. Zhu, H. Yuan, M. Chu, and B. Wen, "Modification of cardiac transcription factor Gata 6 by SUMO," *Biochimie*, vol. 170, pp. 212–218, 2020.

[37] J. Wang, H. Zhang, D. Iyer, X. H. Feng, and R. J. Schwartz, "Regulation of Cardiac Specific nKx2.5 Gene Activity by Small Ubiquitin-like Modifier1," *Journal of Biological Chemistry*, vol. 283, no. 34, pp. 23235–23243, 2008.

[38] E. Y. Kim, L. Chen, Y. Ma et al., "Expression of sumoylation deficient Nkx2.5 mutant in Nkx2.5 haploinsufficient mice leads to congenital heart defects," *PloS One*, vol. 6, no. 6, article e20803, 2011.

[39] E. Y. Kim, L. Chen, Y. Ma et al., "Enhanced desumoylation in murine hearts by overexpressed SENP2 leads to congenital heart defects and cardiac dysfunction," *Journal of molecular and cellular cardiology*, vol. 52, no. 3, pp. 638–649, 2012.

[40] S. H. Rizvi, D. Shao, Y. Tsukahara et al., "Oxidized GAPDH transfers S-glutathionylation to a nuclear protein sirtuin-1 leading to apoptosis," *Free Radical Biology and Medicine*, vol. 174, pp. 73–83, 2021.

[41] N. A. Rashdan, B. Shrestha, and C. B. Pattillo, "S-glutathionylation, friend or foe in cardiovascular health and disease," *Redox Biology*, vol. 37, p. 101693, 2020.

[42] R. A. Cohen and T. Adachi, "Nitric-oxide-induced vasodilatation: regulation by physiologic s-glutathiolation and pathologic oxidation of the sarcoplasmic endoplasmic reticulum calcium ATPase," *Trends in Cardiovascular Medicine*, vol. 4, pp. 109–114, 2006.

[43] R. S. Zee, C. B. Yoo, D. R. Pimentel et al., "Redox regulation of sirtuin-1 byS-glutathiolation," *Antioxidants & Redox Signaling*, vol. 13, no. 7, pp. 1023–1032, 2010.

[44] N. Frey and E. N. Olson, "Cardiac hypertrophy: the good, the bad, and the ugly," *Annual Review of Physiology*, vol. 45, pp. 79, 2003.

[45] S. H. Park, O. Ozden, H. Jiang et al., "Sirt 3, mitochondrial ROS, ageing, and carcinogenesis," *International Journal of Molecular Sciences*, vol. 12, no. 9, pp. 6226–6239, 2011.

[46] V. B. Pillai, S. Samant, N. R. Sundaresan et al., "Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3," *Nature communications*, vol. 6, no. 1, p. 6656, 2015.

[47] M. D. Hirschey, T. Shimazu, E. Goetzman et al., "SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation," *Nature*, vol. 464, no. 7285, pp. 121–125, 2010.

[48] T. Chen, J. Liu, N. A. Li et al., "Mouse SIRT3 attenuates hypertrophy-related lipid accumulation in the heart through the deacetylation of LCAD," *PloS One*, vol. 10, no. 3, article e0118909, 2015.

[49] J. Li, J. Huang, J. Lu et al., "Sirtuin 1 represses PKC-ζ activity through regulating interplay of acetylation and phosphorylation in cardiac hypertrophy," *British Journal of Pharmacology*, vol. 3, pp. 416–435, 2018.

[50] S. Yamamura, Y. Izumiya, S. Araki et al., "Cardiomyocyte Sirt (sirtuin) 7 ameliorates stress-induced cardiac hypertrophy by interacting with and deacetylating GATA4," *Hypertension*, vol. 75, no. 1, pp. 98–108, 2020.

[51] S. Li, Z. Zhu, M. Xue et al., "Fibroblast growth factor 21 protects the heart from angiotensin II-induced cardiac hypertrophy and dysfunction via SIRT1," *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease*, vol. 1865, no. 6, pp. 1241–1252, 2019.

[52] W. Z. Zhu, D. El-Nachef, X. Yang, D. Ledee, and A. K. Olson, "O-GlcNAc transferase promotes compensated cardiac function and protein kinase A O-GlcNAcylation during early and established pathological hypertrophy from pressure overload," *Journal of the American Heart Association*, vol. 8, no. 11, article e01260, 2019.

[53] X. Guo, Y. Deng, L. Zhan, J. Shang, and H. Liu, "O-GlcNAcylation contributes to intermittent hypoxia-associated vascular dysfunction via modulation of MAPKs but not CaMKII pathways," *Molecular Medicine Reports*, vol. 24, no. 5, pp. 5, 2021.

[54] A. Lee, D. Jeong, S. Mitsuyama et al., "The role of SUMO-1 in cardiac oxidative stress and hypertrophy," *Antioxidants & Redox Signaling*, vol. 21, no. 14, pp. 1986–2001, 2014.

[55] C. Y. Huang, C. H. Kuo, P. Y. Pai et al., "Inhibition of HSF2 SUMOylation via MEL18 upregulates IGF-1IR and leads to hypertension-induced cardiac hypertrophy," *International Journal of Cardiology*, vol. 257, pp. 283–290, 2018.

[56] A. Bernt, A. Y. Rangel, M. Eden et al., "Sumoylation-independent activation of calcineurin-NFAT-signaling via SUMO2 mediates cardiomyocyte hypertrophy," *Scientific Reports*, vol. 6, no. 1, 2016.
[57] L. Wang, P. Wang, S. Xu et al., “The cross-talk between PAR-ylation and SUMOylation in C/EBPβ at K134 site participates in pathological cardiac hypertrophy,” International Journal of Biological Sciences, vol. 18, no. 2, pp. 783–799, 2022.

[58] K. A. Hershberger, D. M. Abraham, A. S. Martin et al., “Sir- tuin 5 is required for mouse survival in response to cardiac pressure overload,” Journal of Biological Chemistry, vol. 292, no. 48, pp. 19767–19781, 2017.

[59] K. A. Hershberger, D. M. Abraham, J. Liu, J. W. Locasale, P. A. Grimsrud, and M. D. Hirschy, “Ablation of Sir-tuin5 in the postnatal mouse heart results in protein succinylation and normal survival in response to chronic pressure over- load,” The Journal of Biological Chemistry, vol. 293, no. 27, pp. 10630–10645, 2018.

[60] D. R. Pimentel, T. Adachi, Y. Ido et al., "Strain-stimulated hypertrophy in cardiac myocytes is mediated by reactive oxygen species-dependent Ras_S_gluathiolation,” Journal of molecular and cellular cardiology, vol. 41, no. 4, pp. 613–622, 2006.

[61] M. H. Jeong, H. J. Jeong, B. Y. Ahn et al., “PRMT1 suppresses ATF4-mediated endoplasmic reticulum response in cardio-myocytes,” Cell death & disease, vol. 10, no. 12, p. 903, 2019.

[62] S. Cai, R. Liu, P. Wang et al., “PRMT5 prevents cardiomyo-cyte hypertrophy via symmetric dimethylating HoxA9 and repressing HoxA9 expression,” Frontiers in Pharmacology, vol. 11, 2020.

[63] M. Chen, B. Yi, and J. Sun, “Inhibition of cardiomyocyte hypertrophy by protein arginine methyltransferase 5,” Journal of Biological Chemistry, vol. 289, pp. 24325–24335, 2014.

[64] W. H. Wilson Tang, W. Tong, K. Shrestha et al., “Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure,” European Heart Journal, vol. 29, no. 20, pp. 2506–2513, 2008.

[65] D. M. Yellon and D. J. Hausenloy, “Myocardial reperfusion injury,” New England Journal of Medicine, vol. 357, no. 11, pp. 1121–1135, 2007.

[66] S. Boateng and T. Sanborn, “Acute myocardial infarction,” Disease-a-Month, vol. 59, no. 3, pp. 83–96, 2013.

[67] T. Ou, W. Yang, W. Li et al., “SIRT5 deficiency enhances the proliferative and therapeutic capacities of adipose-derived mesenchymal stem cells via metabolic switching,” Clinical and Translational Medicine, vol. 10, no. 5, article e172, 2020.

[68] S. I. Bibli, Z. Zhou, S. Zukunft et al., “Tyrosine phosphorylation of eNOS regulates myocardial survival after an ischaemic insult: role of PYK2,” Cardiovascular research, vol. 113, no. 8, pp. 926–937, 2017.

[69] Y. Leng, Y. Wu, S. Lei et al., “Inhibition of HDAC6 activity alleviates myocardial ischemia/reperfusion injury in diabetic rats: potential role of peroxiredoxin 1 acetylation and redox regulation,” Oxidative Medicine and Cellular Longevity, vol. 2018, Article ID 9494052, 15 pages, 2018.

[70] R. Gogna, E. Madan, M. Khan, U. Pati, and P. Kuppusamy, “p53's choice of myocardial death or survival: oxygen protects infarct myocardium by recruiting p53 onNOS3 promoter through regulation of p53-Lys18acetylation,” EMBO molecular medicine, vol. 5, no. 11, pp. 1662–1683, 2013.

[71] L. Chen, S. Li, J. Zhu et al., “Mangiferin prevents myocardial infarction-induced apoptosis and heart failure in mice by activating the Sirt1/FoxO3a pathway,” Journal of cellular and molecular medicine, vol. 25, no. 6, pp. 2944–2955, 2021.

[72] B. Xie, X. Liu, J. Yang, J. Cheng, J. Gu, and S. Xue, “PIAS1 protects against myocardial ischemia-reperfusion injury by stimulating PPARy SUMOylation,” BMC Cell Biology, vol. 19, no. 1, p. 24, 2018.

[73] Y. Chen, T. Xu, M. Li et al., “Inhibition of SENP2-mediated Akt de SUMOylation promotes cardiac regeneration via activating Akt pathway,” Clinical Science, vol. 6, pp. 811–822, 2021.

[74] J. Du, L. Zhang, S. Zhuang, G. J. Qin, and T. C. Zhao, “HDAC4 degradiation mediates HDAC inhibition-induced protective effects against hypoxia/reoxygenation injury,” Journal of cellular physiology, vol. 230, no. 6, pp. 1321–1331, 2015.

[75] Y. Gao, Y. Zhao, A. Yuan et al., “Effects of farnesoid-X-receptor SUMOylation mutation on myocardial ischemia/ reperfusion injury in mice,” Experimental Cell Research, vol. 371, no. 2, pp. 301–310, 2018.

[76] S. Lancel, J. Zhang, A. Evangelista et al., “Nitroxy activates SERCA in cardiac myocytes via glutathiolation of cysteine 674,” Circulation research, vol. 104, no. 6, pp. 720–723, 2009.

[77] A. Pastore and F. Piemonte, “Protein glutathionylation in cardiovascular diseases,” International Journal of Molecular Sciences, vol. 14, no. 10, pp. 20845–20876, 2013.

[78] Y. R. Chen, C. L. Chen, D. R. Pfeiffer, and J. L. Zweier, “Mitochondrial Complex II in the Post-ischemic Heart;” The Journal of Biological Chemistry, vol. 282, no. 45, pp. 32640–32654, 2007.

[79] E. Tanai and S. Frantz, “Pathophysiology of heart failure,” Comprehensive Physiology, vol. 1, pp. 187–214, 2015.

[80] B. Ziaei and G. C. Fonarow, “Epidemiology and aetiology of heart failure,” Nature Reviews. Cardiology, vol. 13, no. 6, pp. 368–378, 2016.

[81] B. A. Steinberg, X. Zhao, P. A. Heidenreich et al., “Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction,” Circulation, vol. 126, no. 1, pp. 65–75, 2012.

[82] P. Umapathi, O. O. Mesubi, P. S. Banerjee et al., “ExcessiveO-GlcNAcylation causes heart failure and sudden death,” Circulation, vol. 143, no. 17, pp. 1687–1703, 2021.

[83] Y. Nakagawa, T. Nishikimi, K. Kuwahara et al., “miR30-GLANT1/2 axis-mediated glycosylation contributes to the increased secretion of inactive human prohormone for brain natriuretic peptide (proBNP) from failing hearts,” Journal of the American Heart Association, vol. 6, no. 2, 2017.

[84] K. Kuwahara, Y. Nakagawa, and T. Nishikimi, “Cutting edge of brain natriuretic peptide (BNP) research—the diversity of BNP immunoreactivity and its clinical relevance,” vol. 82, no. 10, pp. 2455–2461, 2018.

[85] A. Mattiazzi and E. G. Kranias, “The role of CaMKII regulation of phospholamban activity in heart disease,” Frontiers in Pharmacology, vol. 5, p. 5, 2014.

[86] O. Copeland, S. Sadayappan, A. E. Messer, G. J. M. Steinen, J. van der Velden, and S. B. Marston, “Analysis of cardiac myosin binding protein-C phosphorylation in human heart muscle,” Journal of Molecular and Cellular Cardiology, vol. 49, no. 6, pp. 1003–1011, 2010.

[87] B. Wang, J. Nie, L. Wu et al., “AMPKα2 protects against the development of heart failure by enhancing mitophagy via PINK1 phosphorylation,” Circulation Research, vol. 122, no. 5, pp. 712–729, 2018.
[88] M. Bouvet, E. Dubois-Deruy, A. Turkieh et al., “Desmin aggrephagy in rat and human ischemic heart failure through PKCζ and GSK3β as upstream signaling pathways,” Cell death discovery, vol. 7, no. 1, p. 153, 2021.

[89] P. A. Gorski, S. P. Jang, D. Jeong et al., “Role of SIRT1 in modulating acetylation of the sarco-endoplasmic reticulum Ca2+-ATPase in heart failure,” Circulation Research, vol. 124, no. 9, pp. e63–e80, 2019.

[90] S. Sun, C. Wang, and J. Weng, “Micro RNA-138-5p drives the progression of heart failure via inhibiting sirtuin 1 signaling,” Molecular Medicine Reports, vol. 23, no. 4, p. 4, 2021.

[91] E. J. Vazquez, J. M. Berthiaume, V. Kamath et al., “Mitochondrial chondrial I defect and increased fatty acid oxidation enhance protein lysine acetylation in the diabetic heart,” Cardiovascular Research, vol. 107, no. 4, pp. 453–465, 2015.

[92] T. Wang, Y. Cao, Q. Zheng et al., “SENP1-Sirt3 signaling controls mitochondrial protein acetylation and metabolism,” Molecular Cell, vol. 75, no. 4, pp. 823–834.e5, 2019.

[93] N. R. Sundaresan, S. Bindu, V. B. Pillai et al., “SIRT3 blocks aging-associated tissue fibrosis in mice by deacetylating and activating glycerol synthase kinase 3β,” Molecular and cellular biology, vol. 5, pp. 678–692, 2015.

[94] E. Renguet, A. Ginion, R. Gélinas et al., “Metabolism and acetylation contribute to leucine-mediated inhibition of cardiac glucose uptake,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 313, no. 2, pp. H432–H445, 2017.

[95] M. Ezzitouny, E. Roselló-Lletí, M. Portolés et al., “Acetylation of patients SERCA2a as a biomarker for the identification of patients with heart failure requiring circulatory support,” Journal of Personalized Medicine, vol. 11, no. 11, p. 1122, 2021.

[96] C. Kho, A. Lee, D. Jeong et al., “SUMO1-dependent modulation of SERCA2a in heart failure,” Nature, vol. 477, no. 7366, pp. 601–605, 2011.

[97] T. J. Samuel, R. P. Rosenberry, S. Lee, and Z. Pan, “Correcting calcium dysregulation in chronic heart failure using SERCA2a gene therapy,” International Journal of Molecular Sciences, vol. 19, no. 4, p. 1088, 2018.

[98] J. Y. Jin, X. X. Wei, X. L. Zhi, X. H. Wang, and D. Meng, “Drp1-dependent mitochondrial fission in cardiovascular disease,” Acta Pharmacologica Sinica, vol. 42, no. 5, pp. 655–664, 2021.

[99] D. G. Harrison, P. J. Marvar, and J. M. Titze, “Vascular inflammatory cells in hypertension,” Frontiers in Physiology, vol. 3, 2012.

[100] G. A. Roth, C. Johnson, A. Abajobir et al., “Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015,” Journal of the American College of Cardiology, vol. 1, pp. 1–25, 2017.

[101] D. Konukoglu and H. Uzun, “Endothelial dysfunction and hypertension,” Advances in Experimental Medicine and Biology, vol. 956, pp. 511–540, 2017.

[102] Y. Zhang, S. You, Y. Tian et al., “WWP2 regulates SIRT1-STAT3 acetylation and phosphorylation involved in hypertensive angiopathies,” Journal of cellular and molecular medicine, vol. 24, no. 16, pp. 9041–9054, 2020.

[103] A. Boguslavskiy, S. Tokar, O. Prysyazhna et al., “Phospholipase phosphorylation regulates vascular tone, blood pressure, and hypertension in mice and humans,” Circulation, vol. 143, no. 11, pp. 1123–1138, 2021.

[104] M. Kirça and A. Yeşilkaya, “Losartan inhibits EGFR transactivation in vascular smooth muscle cells,” Turkish Journal of Medical Sciences, vol. 48, no. 6, pp. 1364–1371, 2018.

[105] S. A. Samant, H. J. Zhang, Z. Hong et al., “SIRT3 deacetylases and activates OPA1 to regulate mitochondrial dynamics during stress,” Molecular and Cellular Biology, vol. 34, no. 5, pp. 807–819, 2014.

[106] A. E. Dikalova, A. Pandey, L. Xiao et al., “Mitochondrial deacetylase Sirt 3 reduces vascular dysfunction and hypertension while Sirt 3 depletion in essential hypertension is linked to vascular inflammation and oxidative stress,” Circulation Research, vol. 126, no. 4, pp. 439–452, 2020.

[107] N. N. Soe, M. Soowen, P. Baskaran et al., “Acetylation of cyclophilin A is required for its secretion and vascular cell activation,” Cardiovascular Research, vol. 101, no. 3, pp. 443–453, 2014.

[108] V. V. Lima, F. R. Giachini, H. Choi et al., “Impaired vasodilator activity in deoxycorticosterone acetate-salt hypertension is associated with increased protein O-GlcNAcylation,” Hypertension, vol. 53, no. 2, pp. 166–174, 2009.

[109] R. H. Hilgers, D. Xing, K. Gong, Y. F. Chen, J. C. Chatham, and S. Oparil, “Acute O-GlcNAcylation prevents inflammation-induced vascular dysfunction,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 303, no. 5, pp. H513–H522, 2012.

[110] V. Lima, F. Giachini, D. Hardy, R. C. Webb, and R. C. Tostes, “O-GlcNAcylation: a novel pathway contributing to the effects of endothelin in the vasculature,” vol. 300, no. 2, pp. R236–R250, 2011.

[111] T. Nagy, V. Champattanachai, R. B. Marchase, and J. C. Chatham, “Glucosamine inhibits angiotensin II-induced cytoplasmic Ca2+ elevation in neonatal cardiomyocytes via protein-associated O-linked N-acetylgalactosamine,” American Journal of Physiology-Cell Physiology, vol. 290, no. 1, pp. C57–C65, 2006.

[112] V. V. Lima, F. R. Giachini, F. S. Carneiro et al., “O-GlcNAcylation contributes to augmented vascular reactivity induced by endothelin 1,” Hypertension, vol. 55, no. 1, pp. 180–188, 2010.

[113] Z. Cai, Z. Wang, R. Yuan et al., “Redox-sensitive enzyme SENP3 mediates vascular remodeling via de-SUMOylation of β-catenin and regulation of its stability,” EBioMedicine, vol. 67, article 103386, 2021.

[114] Z. B. Zhang, C. C. Ruan, D. R. Chen, K. Zhang, C. Yan, and P. J. Gao, “Activating transcription factor 3 SUMOylation is involved in angiotensin II- induced endothelial cell inflammation and dysfunction,” Journal of Molecular and Cellular Cardiology, vol. 92, pp. 149–157, 2016.

[115] Y. R. Kim, J. S. Jacobs, Q. Li et al., “SUMO2 regulates vascular endothelial function and oxidative stress in mice,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 317, no. 6, pp. H1292–H1300, 2019.

[116] E. Y. Kim, Y. Zhang, B. Ye et al., “Involvement of activated SUMO-2 conjugation in cardiomyopathy,” Biochimica et Biophysica Acta, vol. 1852, no. 7, pp. 1388–1399, 2015.

[117] C. A. Chen, T. Y. Wang, S. Varadharaj et al., “S-gluthionylation uncouples eNOS and regulates its cellular and vascular function,” Nature, vol. 468, no. 7327, pp. 1115–1118, 2010.

[118] T. Adachi, D. R. Pimentel, T. Heibeck et al., “S-Glutathiolation of Ras Mediates Redox-sensitive Signaling by Angiotensin II in Vascular Smooth Muscle Cells* [boxes],” The Journal of Biological Chemistry, vol. 279, no. 28, pp. 29857–29862, 2004.
[119] G. K. Hansson and A. Hermansson, “The immune system in atherosclerosis,” Nature Immunology, vol. 12, no. 3, pp. 204–212, 2011.

[120] P. Libby, J. E. Buring, L. Badimon et al., “Atherosclerosis,” Nature Reviews. Disease Primers, vol. 5, no. 1, p. 56, 2019.

[121] W. G. Members, D. Mozaffarian, E. J. Benjamín et al., “Heart disease and stroke statistics–2016 update: a report from the American Heart Association,” Circulation, vol. 4, pp. e38–360, 2016.

[122] L. An, Q. Liu, H. Feng et al., “Increased glycoprotein acetylation is associated with high cardiac event rates: analysis with coronary computed tomography angiography,” Anatolian Journal of Cardiology, vol. 3, pp. 152–158, 2018.

[123] L. Liu, L. Fan, M. Chan et al., “PPARy deacetylation confers the antiatherogenic effect and improves endothelial function in diabetes treatment,” Diabetes, vol. 69, no. 8, pp. 1793–1803, 2020.

[124] S. Ayyadevara, M. Balasubramaniam, S. Kakraba, R. Alla, J. L. Mehta, and R. J. Shmookler Reis, “Aspirin-mediated acetylation protects against multiple neurodegenerative pathologies by impeding protein aggregation,” Antioxidants & Redox Signaling, vol. 27, no. 17, pp. 1383–1396, 2017.

[125] F. Finamore, J. L. Reny, S. Malacarne, P. Fontana, and J. C. Sanchez, “A high glucose level is associated with decreased aspirin-mediated acetylation of platelet cyclooxygenase (COX)-1 at serine 529: a pilot study,” Journal of Proteomics, vol. 192, pp. 258–266, 2019.

[126] G. Pelullo and R. Radi, “Biochemistry of protein tyrosine nitration in cardiovascular pathology,” Cardiovascular Research, vol. 75, no. 2, pp. 291–302, 2007.

[127] J. A. DiDonato, K. Aulak, Y. Huang et al., “Site-specific nitration of apolipoprotein A-1 at tyrosine 166 is both abundant within human atherosclerotic plaque and dysfunctional,” The Journal of Biological Chemistry, vol. 289, no. 15, pp. 10276–10292, 2014.

[128] S. Aggarwal, C. M. Gross, R. Rafikov et al., “Nitration of Tyrosine 247 Inhibits Protein Kinase G–1a Activity by Attenuating Cyclic Guanosine Monophosphate Binding,” The Journal of Biological Chemistry, vol. 289, no. 11, pp. 7948–7961, 2014.

[129] V. Starosta, T. Wu, A. Zimman et al., “Differential regulation of endothelial cell permeability by high and low doses of oxidized 1-palmitoyl-2-archidionyl-sn-glycero-3-phosphocholine,” American Journal of Respiratory and Critical Care Medicine, vol. 46, no. 3, pp. 331–341, 2012.

[130] Y. Yu, X. Su, Q. Qin et al., “Yes–associated protein and transcriptional coactivator with PDZ-binding motif as new targets in cardiovascular diseases,” Pharmacological Research, vol. 159, p. 105009, 2020.

[131] N. Nakashima, G. D. Frank, H. Shirai et al., “Novel role of protein kinase C-δ Tyr311 phosphorylation in vascular smooth muscle cell hypertrophy by angiotensin II,” Hypertension, vol. 51, no. 2, pp. 232–238, 2008.

[132] S. Wang, F. Wang, L. Yang et al., “Effects of coal-fired PM2.5 on the expression levels of atherosclerosis-related proteins and the phosphorylation level of MAPK in ApoE−/− mice,” BMC Pharmacology and Toxictology, vol. 21, no. 1, p. 34, 2020.

[133] K. Nonaka, N. Kume, Y. Urata et al., “Serum levels of S-glutathionylated proteins as a risk-marker for arteriosclerosis obliterans,” Circulation Journal, vol. 71, no. 1, pp. 100–105, 2007.

[134] Y. Wang, M. Qiao, J. J. Mieyal, L. M. Asmis, and R. Asmis, “Molecular mechanism of glutathione-mediated protection from oxidized low-density lipoprotein-induced cell injury in human macrophages: role of glutathione reductase and glutaredoxin,” Free Radical Biology & Medicine, vol. 41, no. 5, pp. 775–785, 2006.

[135] J. T. Lock, W. G. Sinkins, and W. P. Schilling, “Effect of protein S-glutathionylation on Ca2+ homeostasis in cultured aortic endothelial cells,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 300, no. 2, pp. H493–H506, 2011.

[136] S. Dehnavi, M. Sadeghi, P. E. Benson, P. Banach, T. Jamialahmadi, and A. Sahelbar, “The role of protein SUMOylation in the pathogenesis of atherosclerosis,” Journal of Clinical Medicine, vol. 8, no. 11, p. 1856, 2019.

[137] C. H. Woo, T. Shishido, C. McClain et al., “Extracellular signal-regulated kinase 5 SUMOylation antagonizes shear stress-induced anti-inflammatory response and endothelial nitric oxide synthase expression in endothelial cells,” Circulation Research, vol. 102, no. 5, pp. 538–545, 2008.

[138] K. S. Heo, E. Chang, C. H. Le NT, E. T. Yeh, K. Fujiwara, and J. I. Abe, “De-SUMOylation enzyme of sentrin/SUMO-specific protease 2 regulates disturbed flow-induced SUMOylation of ERK5 and p53 that leads to endothelial dysfunction and atherosclerosis,” Circulation Research, vol. 112, no. 6, pp. 911–923, 2013.

[139] R. Barry, S. W. John, G. Liccardi et al., “SUMO-mediated regulation of NLRP3 modulates inflammasome activity,” Nature Communications, vol. 9, no. 1, p. 3001, 2018.

[140] K. M. Wadoss and M. S. Willis, “The story so far: post-translational regulation of peroxisome proliferator-activated receptors by ubiquitination and SUMOylation,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 302, no. 3, pp. H515–H526, 2012.

[141] S. H. Choi, S. S. Chung, and K. S. Park, “Re-highlighting the action of PPARy in treating metabolic diseases,” F1000Research, vol. 7, p. 1127, 2018.

[142] E. Chang and J. I. Abe, “Kinase-SUMO networks in diabetes-mediated cardiovascular disease,” Metabolism, vol. 65, no. 5, pp. 623–633, 2016.

[143] S. Tabrez, M. R. Shait Mohammed, N. R. Jabir, and M. I. Khan, “Identification of novel cardiovascular disease associated metabolites using untargeted metabolomics,” Biological Chemistry, vol. 402, no. 6, pp. 749–757, 2021.

[144] S. Sadhukhan, X. Liu, D. Ryu et al., “Metabolomics-assisted proteomics identifies succinylation and SIRT5 as important regulators of cardiac function,” Proceedings of the National Academy of Sciences of the United States of America, vol. 113, no. 16, pp. 4320–4325, 2016.

[145] C. Ao, L. Yu, and Q. Zou, “Prediction of bio-sequence modifications and the associations with diseases,” Briefings in Functional Genomics, vol. 20, no. 1, pp. 1–18, 2021.

[146] F. Meng, Z. Liang, K. Zhao, and C. Luo, “Drug design targeting active posttranslational modification protein isoforms,” Medicinal Research Reviews, vol. 41, no. 3, pp. 1701–1750, 2021.

[147] J. Habibian and B. S. Ferguson, “The crosstalk between acetylation and phosphorylation: emerging new roles for HDAC inhibitors in the heart,” International Journal of Molecular Sciences, vol. 20, no. 1, p. 102, 2018.

[148] M. M. Silva, F. P. de Souza-Neto, I. C. Jesus et al., “Alamantine improves cardiac remodeling induced by transverse...
aortic constriction in mice," *American Journal of Physiology-Heart and Circulatory Physiology*, vol. 320, no. 1, pp. H352–h363, 2021.

[149] K. Budde, C. Sommerer, O. Rissling, M. T. Dieterlen, and M. J. Barten, "Target enzyme activity and phosphorylation of pathway molecules as specific biomarkers in transplantation," *Therapeutic Drug Monitoring*, vol. 38, Supplement 1, pp. S43–S49, 2016.

[150] M. Y. Kim, M. J. Kim, I. S. Yoon et al., "Diazoxide acts more as a PKC-reactivator, and indirectly activates the mitochondrial KATP-channel conferring cardioprotection against hypoxic injury," *British Journal of Pharmacology*, vol. 149, no. 8, pp. 1059–1070, 2006.